Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status

SIMPLE SUMMARY: This retrospective observational study aims at highlighting the response to pertuzumab, trastuzumab and docetaxel treatment (THP), without using anthracycline, in patients with HER2-positive early breast cancer. We add evidence to the suitability of THP in real life to reach higher p...

Descripción completa

Detalles Bibliográficos
Autores principales: Irelli, Azzurra, Parisi, Alessandro, D’Orazio, Carla, Sidoni, Tina, Rotondaro, Silvia, Patruno, Leonardo, Pavese, Francesco, Bafile, Alberto, Resta, Valter, Pizzorno, Laura, Ciuffetelli, Virginia, Dal Mas, Antonella, Calvisi, Giuseppe, Di Sibio, Alessandra, Marzullo, Anna, Zelli, Veronica, Compagnoni, Chiara, Tessitore, Alessandra, Alesse, Edoardo, Ficorella, Corrado, Cortellini, Alessio, Cannita, Katia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220864/
https://www.ncbi.nlm.nih.gov/pubmed/35740668
http://dx.doi.org/10.3390/cancers14123003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220864/
https://www.ncbi.nlm.nih.gov/pubmed/35740668
http://dx.doi.org/10.3390/cancers14123003

Ejemplares similares